Roger B. Cohen

Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors

P. Jänne, J. Engelman, G. Shapiro, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

K. Venkatakrishnan, T. Stinchcombe, M. von Mehren, 2012, Clinical Cancer Research.

Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.

H. Hurwitz, C. Sweeney, E. Chiorean, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma

S. Keefe, N. Pfanzelter, O. Gunnarsson, 2015 .

A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.

A. Jimeno, E. Winquist, R. Cohen, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors

H. Hurwitz, W. Petros, R. Cohen, 2006, Cancer Chemotherapy and Pharmacology.

Assessment of trabectedin (T) induced liver toxicity with correlation to liver morphology in a phase I study of T + pegylated liposomal doxorubicin (PLD).

M. von Mehren, M. Mehren, A. Yver, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.